Ivermectina: la ciencia hace su parte, el resto depende de nosotros

Roberta Villa | News | 07 April 2023

A pesar de las abundantes pruebas de su ineficacia, sigue habiendo estudios abiertos con este fármaco. ¿Es ético?

Tras una revisión Cochrane que ya hace un año rechazó el uso de la ivermectina en las formas leves y moderadas de COVID-19 y otros tres grandes ensayos aleatorizados , realizados en decenas de miles de personas, que llegaron a la misma conclusión, JAMA publica esta semana los últimos resultados...

Ivermectina: la ciencia hace su parte, el resto depende de nosotros

December Challenge

What are the maternal risk factors for cerebral palsy in children?

Are assisted reproductive technologies associated with an increased risk for cardiovascular disease in nulliparous women?

How do different dosages of gabapentin affect pain intensity in patients undergoing spine surgery?

Does the Mediterranean diet have protective effects on adverse pregnancy outcomes?

What is the most effective digitally assisted intervention to reduce glycated haemoglobin?

How effective is endoscopic screening in reducing the risk for gastric cancer mortality?

What is the association between apolipoproteins and metabolic syndrome?

Can tumour-infiltrating lymphocyte scores affect treatment decisions?

Do different exercise training modes have different effects on resting blood pressure?

How are neurocutaneous syndromes associated with central nervous system tumours in childhood?

Topic Challenges

Quiz challenge Emerging diseases: COVID-19

ESMO 2020 topic challenge

Women's health challenge

Antibiotics - Consequence of MDR carriage

Neurological disorders challenge

Rheumatology challenge

Lyme Disease

Mental health challenge

Topic challenge - Children conditions

Lyme Disease